Brokers Offer Predictions for ABEO Q1 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Abeona Therapeutics in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will earn ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19.

ABEO has been the subject of several other research reports. Oppenheimer began coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Down 0.6 %

Shares of ABEO opened at $5.12 on Tuesday. The company has a market capitalization of $222.57 million, a P/E ratio of -1.90 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The business’s 50 day simple moving average is $5.43 and its 200-day simple moving average is $5.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ABEO. Charles Schwab Investment Management Inc. bought a new stake in shares of Abeona Therapeutics during the third quarter worth $151,000. Citigroup Inc. raised its holdings in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the last quarter. Western Standard LLC lifted its position in Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $84,000. Finally, XTX Topco Ltd acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $160,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.